Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,695 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON.
Hartmaier RJ, Markovets AA, Ahn MJ, Sequist LV, Han JY, Cho BC, Yu HA, Kim SW, Yang JC, Lee JS, Su WC, Kowalski DM, Orlov S, Ren S, Frewer P, Ou X, Cross DAE, Kurian N, Cantarini M, Jänne PA. Hartmaier RJ, et al. Among authors: ren s. Cancer Discov. 2023 Jan 9;13(1):98-113. doi: 10.1158/2159-8290.CD-22-0586. Cancer Discov. 2023. PMID: 36264123 Free PMC article.
Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas.
Pishvaian M, Morse MA, McDevitt J, Norton JD, Ren S, Robbie GJ, Ryan PC, Soukharev S, Bao H, Denlinger CS. Pishvaian M, et al. Among authors: ren s. Clin Colorectal Cancer. 2016 Dec;15(4):345-351. doi: 10.1016/j.clcc.2016.07.009. Epub 2016 Aug 4. Clin Colorectal Cancer. 2016. PMID: 27591895 Clinical Trial.
Population Pharmacokinetics of Monalizumab in Patients With Advanced Solid Tumors.
Hwang M, Fan C, Yue MS, Zhou D, Paturel C, Andre P, Cheng LY, Mitchell P, Kourtesis P, Ruscica D, Das M, Morsli N, Ren S, Gibbs M, Phipps A, Song X. Hwang M, et al. Among authors: ren s. J Clin Pharmacol. 2023 Jul;63(7):817-829. doi: 10.1002/jcph.2220. Epub 2023 Apr 10. J Clin Pharmacol. 2023. PMID: 36852723
Evolving drug regulatory landscape in China: A clinical pharmacology perspective.
Tang W, Huang Y, Zhou D, Huang Y, Chen Y, Ren S, Li Y, Wu S, Zhao X, Song X, Wang H, Jin Y, Yu H, Zhang L, Li Y, Boulton D, Shen K. Tang W, et al. Among authors: ren s. Clin Transl Sci. 2021 Jul;14(4):1222-1230. doi: 10.1111/cts.12987. Epub 2021 Feb 23. Clin Transl Sci. 2021. PMID: 33503308 Free PMC article. Review.
A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men.
Sakamoto K, Matsuki S, Irie S, Uchida N, Hayashi N, Horiuchi M, Ren S. Sakamoto K, et al. Among authors: ren s. Clin Pharmacol Drug Dev. 2020 Oct;9(7):833-840. doi: 10.1002/cpdd.775. Epub 2020 Jan 20. Clin Pharmacol Drug Dev. 2020. PMID: 31960624 Free PMC article. Clinical Trial.
4,695 results